Results 251 to 260 of about 553,015 (386)

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

open access: yes
Arthritis &Rheumatology, EarlyView.
Stephen J. Balevic   +2 more
wiley   +1 more source

Single‐cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosus

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang   +9 more
wiley   +1 more source

Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a long‐term multicenter observational study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Osteoporosis causes fractures which further increase the disease burden of rheumatoid arthritis (RA), however, osteoporosis treatment rates remain low. While several studies have reported that biologic or targeted synthetic disease‐modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis in RA, our large‐scale, real ...
Takafumi Aritomi   +30 more
wiley   +1 more source

Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Prospective Cohort Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To examine the association between radiographic structural damage and physical function (PF) in psoriatic arthritis (PsA). Methods Data were analyzed from a large longitudinal PsA cohort. PF was measured using the Health Assessment Questionnaire (HAQ, 0‐3) and Short Form‐36 PF subscale (SF‐36, 0‐100); radiographic joint damage using modified ...
Pankti Mehta   +8 more
wiley   +1 more source

Interleukin‐2 deprived state of regulatory T cells and their recovery by low‐dose interleukin‐2 in patients with inflammatory myopathies

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Regeneration and expansion of regulatory T cells (Treg) by low‐dose interleukin‐2 (IL‐2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically‐based rationale for low‐dose IL‐2 therapy, we investigated whether reversible defects in the Treg‐IL‐2 axis emerge in ...
Justus Ohmes   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy